MR HANR

[MR HANR @alinasser0033]

@mMichaelNgu4229 Don’t wait a year or two it’s much closer than that. We’re talking about a multi-billion dollar acquisition, and big pharma won’t let IXHL slip away. This is massive revenue for them and a once-in-a-lifetime opportunity.

[MR HANR @alinasser0033]

@Turki_alalshikh هذا لازم تجيبله مركه ابوناصر 🙃

[MR HANR @alinasser0033]

@Turki_alalshikh ولا بعد متركي ابداع الداع👏🏻👏🏻👏🏻👏🏻

[MR HANR @alinasser0033]

@Ahmedalsamel1 IXHL

[MR HANR @alinasser0033]

@gorgeous4ew وجب حظر الحساب

[MR HANR @alinasser0033]

🚨 $IXHL | The Critical Phase Begins Now

Incannex has just announced the appointment of a powerful Clinical Advisory Board for its IHL-42X program, featuring top-tier sleep medicine experts from Harvard and Emory‼️

https://t.co/clMdrT3IJQ

[MR HANR @alinasser0033]

$ixhl #ixhl

Opportunities don’t knock twice...
Today, you're looking at a stock with all the ingredients for a massive breakout:

✅ Dilution canceled
✅ FDA Phase 3 approval secured
✅ Phase 2 results coming soon
✅ Talks of a partnership or acquisition
✅ And short sellers are cornered with over 340% borrow cost!

This isn’t just a trade this is a battle of positions...
Those who hold through today might witness a life-changing moment when the announcement hits.

Patience during critical moments is what creates legends
The countdown has begun and the stock is still near the bottom!

⏳ Get ready... the explosion is coming.

[MR HANR @alinasser0033]

If IXHL is acquired, Phase 3 funding becomes fully secured with no further dilution. A strategic partner or acquirer would cover all future costs, and IXHL would likely be revalued based on the future potential of its drug—not its current market price.

📌 Most importantly: the company has officially confirmed that commercial discussions are already underway. That’s a strong signal that serious players are already engaged, just waiting for the Phase 2 results to finalize a deal.

[MR HANR @alinasser0033]

In the world of stocks, rare moments arise when opportunity, timing, and price align.

IXHL isn’t just another ticker — it’s a potential game-changer with the first-ever oral drug for OSA, impacting over 1B people globally.

✅ FDA-cleared Phase 3
✅ No direct competitors
✅ 347M+ dilution-threatened shares cancelled
✅ Market cap under $7M (!?)
✅ Strategic partner/acquisition potential
✅ Phase 2 results in July
✅ Visible smart-money accumulation
🧠 Wealth is made by holding bottoms, not chasing tops.
Current weakness = noise before liftoff.
🚀 Hold now → 5x, 10x or more.
Exit now → Watch it from the sidelines with regret.
$IXHL — not a trade. A turning point.
#Stocks #BiotechStocks #FDAApproval #SmallCaps #GrowthStocks #Investing #Trading #IXHL #SleepApnea #Healthcare #PennyStocks #ShortSqueeze #Breakout #Biotech #Bullish #PharmaStocks

[MR HANR @alinasser0033]

🚨 Not every day a company gets FDA early clearance for Phase 3 before even announcing Phase 2 results!

✅ But $IXHL did. That’s how strong and convincing their therapy is — the FDA is already on board.

📉 Most companies wait months or years for this. IXHL just skipped the line.

💊 This isn’t just any drug. It could be the first of its kind worldwide — and the world is watching.

🔥 If early approval already happened… imagine what comes next when results hit?

🚀 The explosion is coming. Be ready.

[MR HANR @alinasser0033]

SPCE حالياً في مرحلة هبوط طويلة، والسعر عند 3.72 بعد ما شريته على 6$.
هل بيرجع لـ 6؟ ممكن، بس ما راح يصير بسرعة إلا إذا طلع خبر قوي جدًا مثل تجربة فضائية ناجحة أو تمويل كبير.

منطقياً، السهم يحتاج يكسر منطقة 4.20 أول، ومع فوليوم عالي عشان يبدأ يستعيد الثقة.
غير كذا، راح يظل يتداول بين 3.50 و4.00 ما لم يظهر محفز واضح.

نصيحتي؟ تابع السهم، وإذا ناوي تعدل متوسطك، خذ القرار على دعم قوي، مو عشوائي.

[MR HANR @alinasser0033]

🚨 Message to all $IXHL short sellers:

Your time is up.

🔥 The vote is coming Tuesday — and with it, the biggest weapon you relied on (175M phantom shares) will be canceled.
🔥 Borrow fees are above 350%, and the float has vanished.
🔥 Phase 2 clinical results are near, and the holders are ready for war.
📉 There’s no escape... short covering is inevitable.
🧨 IXHL will not be sold cheap.
🛑 There is no exit — only pain.
The end of short selling begins now.
#IXHL #ShortSqueeze #Biotech #IHL42X #NoMoreDilution

[MR HANR @alinasser0033]

هلا علي

بالنسبة لـ IXHL، صحيح الشركة ألغت نص الـ Warrants، لكن ما أعلنت لسه عن مصير النصف الثاني. فممكن فعلاً يصير فيه تخفيف إضافي قريب، خصوصًا بعد اجتماع 27 مايو.

عشان كذا أنا متابع الوضع بدقة، وما دخلت عشوائي. داخل على 0.28 ومترقب إعلان رسمي بانتهاء التخفيف. إذا أعلنوا فعلاً إنهم خلصوا من كل التخفيف أو أرفقوه بنتائج إيجابية، السهم وقتها ممكن يعطي انفجار سعري.

فباختصار: أي نزول ممكن يصير على المدى القصير بسبب التخفيف، لكن إذا التخفيف خلص رسميًا + جاء خبر IHL-42X، ممكن نشوف أرقام عالية جدًا.بأذن الله

[MR HANR @alinasser0033]

🚨 $IXHL is not a one-shot biotech.

💊 Two active drugs in play:

1️⃣ IHL-42X – Phase 2 completed. FDA meeting coming. Potential breakthrough for 1B+ OSA patients.

2️⃣ CannQuit-O – FDA pre-IND meeting done. CBD + opioid antagonist chewable for OUD. Ready for clinical launch.

🔥 Massive short interest. CTB 350%+. 114% of float sold short.

🎯 Double-pipeline. Double pressure.

#IXHL #Biotech #ShortSqueeze #Cannabis #FDA

[MR HANR @alinasser0033]

$ixhl #ixhl

https://t.co/9AAnv5wdm5

[MR HANR @alinasser0033]

🔔 Double Alert – $IXHL #IXHL is Hitting Short Sellers from Both Sides!

📌 Breaking Official News:

Incannex ($IXHL) has successfully raised $16.7M
Out of that, $12.5M will be used to cancel 50.4% of Series A Warrants
✅ This move prevents up to 175.2 million new shares from being issued
📉 Result: Massive reduction in dilution risk and boosted investor confidence
📈 Technically, the setup is explosive:
⚠️ Borrow Fee: 421%
⚠️ Short Interest exceeds float: 136%
⚠️ Shorted shares: 29.7M
⚠️ Days to cover: 0.82
🔥 Short Score: 80/100
📉 This setup mirrors what we saw in $GME and $AMC during their historic squeezes
📢 Bottom Line:
📊 Strong fundamental news + extreme short pressure =
🚀 High potential for a Short Squeeze in the coming hours

⏳ Everything is in place… and the market smells panic.
#IXHL #ShortSqueeze #Warrants #Biotech #OptionsFlow

[MR HANR @alinasser0033]

Incannex (IXHL) is in a pre-explosion stage — literally on the launchpad.
$IXHL #IXHL
🚨 Borrow fee has exploded past 550%
🚨 Utilization is at 98.4% – almost maxed out
🚨 Over 20 million shares sold short
🚨 Shortable shares are nearly gone
🚨 Short interest is 19.19% of the float and climbing fast
🚨 Days to cover: 6.7 — a disaster waiting to happen if the price moves up

⚡️ All of this = ROCKET FUEL — just waiting for a spark.
And the spark is coming: IHL-42X clinical results are near, and institutional support is solid.

🎯 Price projection if it ignites:

🚀 From $0.26 →
➡️ $1.00
➡️ $2.50
➡️ $5.00+ within days or even hours.

💥Bottom line:

This isn’t just a setup to launch… it’s a setup to explode.

[MR HANR @alinasser0033]

🔥 $IXHL #IXHL isn't just a stock… it's the key to the entire sector!ResMed has officially acquired VirtuOx 👀
And the goal? To dominate the diagnosis and treatment of Obstructive Sleep Apnea (OSA) – the exact space where IXHL is making waves with its IHL-42X treatment.💥 The surprise?
A member of IXHL’s advisory board comes directly from ResMed…
Same field.
And the timing? Just before the expected Phase 2 trial results!🚨 This isn't a coincidence...
This is a setup for a potential buyout or strategic partnership!
This stock isn’t just loaded with catalysts – it’s a fire waiting to erupt.⚠️ No shares available to short
⚠️ Squeeze pressure building
⚠️ Institutional investors loading silently
⚠️ Entire sector in a FOMO state🎯 Current price? $0.26
📈 Target? Not just $1…
If the rumors catch fire and clinical news drops?
We're talking $5, $20… maybe even GME/HKD levels.🚀 Who wins?
The one who sees it before the explosion.
IXHL is your chance to lead the market – not chase it.

https://t.co/NUZiZnmu6D